Hims & Hers Health, Inc. (NYSE: HIMS) reported Q2 EPS of $0.17, $0.02 better than the analyst estimate of $0.15. Revenue for the quarter came in at $544.8 million versus the consensus estimate of $549.87 million.

GUIDANCE:

Hims & Hers Health, Inc. sees Q3 2025 revenue of $570-590 million, versus the consensus of $584.2 million.

• Adjusted EBITDA of $60 million to $70 million, reflecting an Adjusted EBITDA margin of 11% to 12%.

Hims & Hers Health, Inc. sees FY2025 revenue of $2.3-2.4 billion, versus the consensus of $2.36 billion.

• Adjusted EBITDA of $295 million to $335 million, reflecting an Adjusted EBITDA margin of 13% to 14%.

For earnings history and earnings-related data on Hims & Hers Health, Inc. (HIMS) click here.